The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and ...
The Fast Track designation accelerates troculeucel’s path to U.S. FDA submission for the treatment of patients with moderate Alzheimer’s ...
3d
Medical review of Phase 1 cohorts demonstrated no safety issuesData to be presented at the 10th Annual Innate Killer Summit, March 3-5 BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio ...
The Scientific Review Committee (SRC) charter is to review the safety data from the patients treated in the Phase I portion ...
Shares of Nkarta, Inc. (NASDAQ:NKTX – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...
BOCA RATON, FLORIDA - INmune Bio , Inc. (NASDAQ: NASDAQ:INMB), a clinical-stage biotechnology company with a market capitalization of $212.74 million, announced today its plans to submit regulatory ...
FNDE has attractive valuation and performance metrics in its category, but it is overweight in financials and in China. Read ...
Billions was wiped off the Australian share market on Monday, as the latest phase of the US President’s tariff plans had a direct impact on the domestic market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback